A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis Clinical Trial

Official title:

A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02578914
• Other study ID #: ALDNS2-203-D1
• Secondary ID: 15-MO-001
• Status: Completed
• Phase: Phase 2
• Start date: August 2015
• Est. completion date: December 2015

Study information

• Verified date: May 2016
• Source: Aldeyra Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, parallel, single center, double masked, vehicle controlled study. The purpose of this study is to determine the activity and safety of NS2 in patients with grass, tree or ragweed-pollen induced seasonal allergic conjunctivitis . Subjects will be randomized 1:1 to receive multiple doses of NS2 Ophthalmic Drops (0.5%) or NS2 Ophthalmic Drops Vehicle (0.0%).

Free aldehydes are thought to be related to inflammatory conditions such as allergic conjunctivitis. NS2, a small molecule aldehyde trap, is being evaluated to determine whether it may decrease inflammation by lowering aldehyde levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Graded conjunctival redness in at least one region (nasal or temporal) in each eye at any one time point (not necessarily the same time point) post-CAPT (Conjunctival Allergen Provocation Test) of >2

• Graded ocular itching at any one time point

• Visual acuity of at least 20/50 in each eye

• At least 2 year history of moderate to severe allergic conjunctivitis.

• Positive skin prick test to ragweed, grass and/or tree pollen within one year of Screening Visit (Visit 1).

• Ability to avoid any topical or systemic ocular medications during the entire study period.

Exclusion Criteria:

• Subjects must not have an ocular itching score >0 or a conjunctival redness score >1 prior to CAPT in either eye in any region (nasal or temporal) at Visits 2-4. I

• History of glaucoma, or Intraocular Pressure (IOP) over 25mmHg at the screening visit, or a history of elevated IOP within the past 1 year.

• Ocular surgery, including laser procedures, within the past 12 months of Visit 1.

• Use of glaucoma medications, antibiotics, antivirals, or topical cyclosporine within 1 month of the screening visit.

• History of dry eye syndrome, blepharitis, herpes simplex keratitis or herpes zoster keratitis.

• History of uveitis in the past 3 years.

• Presence of any ocular infection or active ocular inflammation (e.g. follicular conjunctivitis, allergic conjunctivitis) within 14 days prior to start of study (Visit 1).

• History of moderate to severe asthma or allergy induced asthma to the allergen that will be used in CAPT.

• Use of oral corticosteroids within 30 days of screening and throughout the study period; use of intranasal or inhaled corticosteroids within 14 days of screening and throughout the study period.

• Use of antihistamines (ocular, nasal, topical or oral) within 7 days prior to screening (Visit 1) and throughout the study period. Non-medicated artificial tears are allowed up to 72 hours before screening (Visit 1) and throughout the study period.

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic
• Hypersensitivity
• Rhinitis, Allergic, Seasonal
• Seasonal Allergies

Intervention

Drug:
• NS2 Ophthalmic Drops (0.5%)

• NS2 Ophthalmic Drops Vehicle (0.0%)

Locations

Country	Name	City	State
Canada	Inflamax Research Inc.	Mississauga	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Aldeyra Therapeutics, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge	Mean change from baseline in ocular itching score using a 0 to 4 scale (0 = none, 4 = severe) on Day 14, 60 minutes into the allergen challenge. The least squares mean (standard error) was derived from analysis of covariance (ANCOVA) with baseline as a covariate and treatment group as a factor.	The efficacy assessment period was assessed at Day 14; baseline was Day -7.